Page 35 - BSAVA Guide to Pain Management in Small Animal Practice
P. 35
BSAVA Guide to Pain Management in Small Animal Practice
VetBooks.ir Dose Comments
Aspirin
Used as an anti-thrombotic agent
mg kg every third day
Carprofen N A Not recommended
Etodolac N A Not recommended
irocoxib N A Not trialled in cats
Paracetamol N A Contraindicated
acetaminophen
Phenylbutazone N A Not recommended
Prednisolone . mg kg orally h Do not administer NSAIDs concurrently
eloxicam . mg kg orally h on day , Indicated for pain and in ammation in chronic
followed by . mg kg orally musculoskeletal disorders
Robenacoxib mg kg orally h up to days Indicated for pain and in ammation of chronic A,
may be suitable for longer term administration
epoxalin mg kg day No A, but one study found tepoxalin was well
tolerated compared with meloxicam particularly
for urinary tract discomfort (Charlton et al.,
olfenamic acid mg kg orally h up to days Not indicated for chronic pain
Vedaprofen . mg kg orally h up to days Not indicated for chronic pain
Non steroidal anti in ammatory drugs NSAI s and other anti in ammatory and pain relieving products
for use in cats with chronic maladaptive pain. Very few products have long term market authori ation
A and treatment must be closely supervised by a veterinary surgeon. Consult datasheets for further information.
Use the lowest e ective dose and a multimodal approach. All NSAI s are capable of causing gastrointestinal signs
and lesions, and hepatic and renal in ury. Regular monitoring of patients is necessary. A osteoarthritis.
signi cant interpatient variability in terms of
e cacy and side e ects. In animals that show a
lack of response to one NSAID, it is worth
NSAIDs remain the most popular medications considering swapping to another. In cases
for treating chronic pain in dogs and cats. hey where a swap is made it is suggested to allow
reduce the production of in ammatory a 7 day washout period between the drugs
prostaglandins by selective inhibition of the (Kukanich et al., 1 . Sustained release
cyclooxygenase C en yme producing formulations of NSAIDs are being developed
a peripheral anti in ammatory e ect. and trialled.
urthermore, these drugs will cause a reduced
sensitization within the CNS. Several
formulations have market authorization for
long term use in dogs; meloxicam is licensed
for long term use in cats in the U and o attempt to reduce the potential for adverse
guidelines have been developed for long-term events associated with the inhibition of C
use of NSAIDs in cats (Sparkes et al., 1 . en ymes, an EP4 prostaglandin receptor
Recent studies also suggest robenacoxib may antag onist has been studied in client-owned
be safe in cats (King et al., 1 ; ing et al., dogs, which demonstrated improved pain relief
1 . here are no controlled trials compared with placebo (Derra et al., 16 .
demonstrating superiority of one NSAID over Grapiprant is planned for release in the UK in
another in OA, and there appears to be early 19.
30
Ch04 Pain Management.indd 30 19/12/2018 10:35